NASDAQ
1.48USD
+0.12 (+8.46%)
We have scored 3 news catalysts on PMV Pharmaceuticals, Inc. (PMVP) over the past 12 months. The biggest single-day move next to one of them came Sep 16, 2026, when PMVP closed +8.8%: “Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?”. Coverage across the window leans positive (average ticker sentiment +0.80). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
78.7M
P/E
—
EPS
—
Beta
1.37
52W range
1.02-1.88
Day range
1.37–1.51
Open
1.37
Prev close
1.36
Volume
747.3K
Avg volume
446.5K
Dividend
0.00
IPO
2020-09-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about PMV Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PMVP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
